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Abstract
Background: Erysipelas is a common infection that often recurs, but the impact of specific risk factors for
reoccurrence remains elusive. In the present study we aimed at clarifying predisposing conditions for reoccurrence.
Methods: Medical records were reviewed from all patients ≥18 years of age diagnosed with erysipelas at the
Department of Infectious Diseases at Skåne University Hospital, Sweden, from January 2007 to February 2011. 502
patients were included, of which 357 were single episode erysipelas and 145 had recurrent erysipelas. These two
groups were compared regarding underlying conditions and clinical presentation.
Results: Erysipelas in the lower limbs had the greatest propensity of recurrence. The associations between
underlying conditions and recurrence were largely depending on the site of erysipelas. Overall, the most prominent
risk factor for recurrence was lymphedema and other conditions causing a chronic impairment of the defence
against microbes. Conditions temporarily disrupting the skin barrier (e.g. a local wound or toe web intertrigo),
although likely being risk factors for erysipelas per se, did not seem to predispose to repeated episodes. Individuals
with recurrent erysipelas tended to seek medical attention earlier, and were less likely to be hospitalized or receive
intravenous antibiotics, but there was no evidence of any difference in inflammatory reaction when taking
confounding factors into account.
Conclusions: In this large cross-sectional study of over 500 patients with erysipelas, lymphedema was the most
prominent risk factors for recurrence although the distribution of predisposing conditions varies depending on the
site of erysipelas.
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Background
Erysipelas is a common infection of the superficial layer
of the skin, in contrast to cellulitis and necrotizing fasci-
itis, which also involve the subcutaneous tissue. It has an
estimated incidence of 19–24 per 10,000 inhabitants in
European countries [1,2]. Erysipelas is defined as an acute
onset of local signs of inflammation such as progressing
erythema, associated with pain and swelling, clearly de-
marcated from the surrounding tissue. In the typical case
erysipelas also manifests with systemic symptoms such as
fever, chills and malaise and sometimes accompanied by
nausea and vomiting [3,4]. The main causative agent is
group A and group G β-hemolytic streptococci. Whether
erysipelas also can be caused by Staphylococcus aureus or
gram-negative bacteria is debated [5-7]. The most com-
mon site of the infection is the lower limb, accounting for
about 80% of all cases [8]. In general erysipelas is a mild
disease with low case-fatality, but a significant part of pa-
tients need in-hospital treatment [9]. The most common
complication is recurrence, which occurs in 12-29% of the
cases [5,10,11].
There are various risk factors reported for erysipelas
including disruption of the cutaneous barrier, venous in-
sufficiency, lymphedema and overweight [12,13]. In the
upper limbs, lymphedema or radical mastectomy are im-
portant risk factors [14], whereas risk factors for recur-
rence are less well defined [15]. Prophylaxis with penicillin
V is sometimes recommended, but treatment criteria are
not well defined. This common infection causes both
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suffering and medical expenses that should motivate ap-
propriate prevention, which should be directed to patients
with the greatest risk [1]. In this study, we hypothesized
that patients with single episode erysipelas and patients
with recurrent erysipelas differs regarding general charac-
teristics and we aimed to clarify risk factors for erysipelas
recurrence. We also aimed at assessing whether the clin-
ical presentation in episodes of recurrent erysipelas differ
from single episodes.
Methods
We identified all patients ≥ 18 years of age, both hospital-
ized and outpatients, diagnosed with erysipelas at the De-
partment of Infectious Diseases, Skåne University Hospital,
Lund Sweden, between January 2007 and February 2011.
The hospital is a university hospital serving 200,000 inhabi-
tants, living in the city of Lund (southern Sweden) and
surroundings. The diagnosis of erysipelas was determined
by the admitting physician. The medical records were
reviewed and data extracted according to a pre-specified
protocol, all data was anonymized before analysis.
The patients were divided into two groups for com-
parison, single episode erysipelas (SE) and recurrent ery-
sipelas (RE). SE was defined as patients with erysipelas
without a history of previous episodes (medical records
and anamnestic information). RE was defined as patients
with more than one episode of erysipelas registered dur-
ing the study period, or anamnestic information of pre-
vious episode outside the study period. Parameters are
shown in the Additional file 1. Malignancy included both
prior and present occurrence of all types. Previous re-
gional operation was defined as surgical interventions at
the area affected by erysipelas or adjacent locations. As a
number of patients from the RE group was registered for
more than one episode (separated by at least 30 days)
during the study period, the medical record from the last
recurrent episode that occurred within the study period
was selected for comparison with the SE group.
The Ethics Committee of Lund University, Sweden (Dnr.
2011/674) approved of the study.
Statistics
Fisher’s exact tests, Chi-squared tests and analysis of
variance were used to assess the distribution of back-
ground factors in individuals with SE and RE, and to as-
sess the distribution of markers of disease severity and
clinical presentation between individuals with SE and
RE. Multiple imputation was used to handle missing data,
using chained equations with 20 imputation sets, see ap-
pendix for details [16,17].
Logistic regression and exact logistic regression was
used to assess predictors of recurrence. We considered
gender, age (linear), localization (lower limbs, upper
limbs, thorax/trunk, head/face) local operation (any
kind), radiation therapy, severe obesity, liver disease,
autoimmune/systemic inflammatory disease, immuno-
suppressive therapy, peripheral arterial insufficiency,
peripheral venous insufficiency, lymphedema, wound,
toe web intertrigo, diabetes mellitus, chronic obstructive
pulmonary disease (COPD), cardiovascular disease, and
polyneuropathy. Covariates assessed in univariable models
were considered for inclusion in multivariable models at a
p-value of <0.2. Due to the anticipated modifying effect of
erysipelas site, separate models were fitted for lower limbs,
upper limbs, thorax and trunk, and head or face. Akaike’s
information criterion was used to assess model fits and
Hosmer and Lemeshow’s goodness-of-fit test in the
complete case analyses was used to test the final models.
Logistic regression was used to assess whether indi-
viduals with recurrent episodes had a milder or more
severe disease presentation, as measured by the need for
hospitalization and/or initial intravenous antibiotics.
Age, localization, time since onset of symptoms (<12 hours,
13–72, >72) were included. Linear regression, adjusted for
site and time since onset, was used to assess differences
in C-reactive protein levels (CRP), (square root of CRP)
and white blood cell counts (WBC), (log value of WBC).
Likelihood ratio tests were used to test for differences
and interactions. All analysis was performed with STATA/
SE (version 12.1; StataCorp LP, USA).
Results
Patient demographics
During the study period, 601 patients were registered
with the diagnosis of erysipelas. Among them, 99 were
excluded due to medical records that could not be re-
trieved, initial erysipelas diagnose that changed to other
diagnose during the episode and non-acute patient visits.
A total of 573 episodes of erysipelas in 502 patients
were identified during 2007–2012. The median age was
60 years (range 18–97), 58% were male. The infection was
located in the lower limbs in 69% of the episodes, in the
upper limbs in 14%, on the thorax or trunk in 8% and in
the head or face in 9%. The episodes were evenly distrib-
uted over the year, with no accumulation in either cold or
warm months. Overall 64% received initial intravenous
antibiotic treatment, and 55% were hospitalized; 30% had
a positive local culture and 5% were bacteraemic.
Three hundred sixty-nine individuals had no previous
history of erysipelas and 133 had a positive history. Forty-
six individuals experienced at least one recurrence during
the study period (median 3 episodes, range 2–5). Nine of
these had no previous history but experienced recurrence
during the study period.
Clinical presentation and disease severity
Individuals with SE, n = 360 (71%), were compared with
those with RE, n = 142 (29%). Neither age (p = 0.06) nor
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the sex distribution (p = 0.36) differed between the groups.
Individuals with RE were more prone to seek medical care
earlier, 33% <12 hours since onset of symptoms vs. 17% in
individuals with SE (p = 0.01), and were less likely to be
hospitalized, adjusted odds ratio (aOR): 0.5 (95% CI:
0.3-0.8) or receive initial intravenous antibiotic treatment
aOR: 0.6 (95% CI: 0.4-0.9), estimated by logistic regression
adjusted for age, localization, time since onset of symp-
toms and underlying co-morbidity. However, there was no
difference in the distribution of the level of CRP (p = 0.90)
or white blood cell (WBC) counts (p = 0.58), estimated in
linear regression models adjusted for time since onset and
localization. In addition, there was no difference in the
length of antibiotic treatment (p = 0.78) nor in the
length of stay (LOS) – analysed among those hospital-
ized (n = 278), aOR for LOS >7 days for RE was 1.1 (95%
CI 0.5-2.3) adjusted for age, severe obesity, malignancy,
COPD, diabetes and localization (p = 0.93). See Table 1
for crude estimates.
Risk factors for recurrent erysipelas
The localization of erysipelas was associated with RE
in univariable analyses, as were venous insufficiency,
lymphedema, severe obesity, previous operation and a
history of malignancy, whereas a local wound and COPD
was positively associated with SE, see Table 2. As antici-
pated, there was a strong heterogeneity (i.e. effect modifi-
cation) caused by the site of erysipelas.
In univariable analyses of erysipelas in the lower limbs
(n = 342) local factors, i.e. skin disease, venous insuffi-
ciency and lymphedema were predictive, see Table 3. In
multivariable analyses, there was statistical evidence for
the association between RE and lymphedema, aOR 4.3
(95% CI 1.3-14.0), venous insufficiency aOR 2.3 (95% CI
1.0-5.2), skin disease aOR 1.9 (95% CI 1.0-3.7) and COPD,
OR 0.2 (95% CI 0.04-1.0). However, effect estimates indi-
cated a four-fold increased risk of recurrence for severe
obesity and a two-fold for previous CABG, although these
did not reach statistical significance.
In erysipelas located in the upper limbs (n = 75), gen-
der, malignancy, local operation, lymphedema and local
wound were predictive in univariable analyses. Due to
the complex relationship between malignancy, operation
and lymphedema, multivariable analyses were performed
in three steps. In the first model, gender, malignancy and
wound was included, in the second, operation and radi-
ation was added, and thirdly lymphedema. The effect of
gender in univariable analysis was completely con-
founded by a history of local operation. The final model
included only operation and lymphedema. All of the ef-
fect of malignancy on the propensity for recurrence was
mediated by a history local operation, aOR: 13.2 (95% CI
2.0-85.4) which in turn was partly mediated by the pres-
ence of lymphedema, aOR: 7.4 (05% CI 0.8-66.1). In uni-
variable analyses, the OR for lymphedema (all patients
with lymphedema had been operated on) was 43.5 (95%
CI: 7.5-249.7). Although analyses were based on small
number, the OR for local operation, from stratified ana-
lysis in individuals without lymphedema, was 28.0 (95%
CI 3.3-236.4), which supports the idea that a local oper-
ation is a strong risk factor for recurrence and that the
effect is enhanced by the development of lymphedema.
When erysipelas was located on thorax or the trunk
(n = 35), only malignancy, OR 10.0 (95% CI 1.1-90.8),
and wound, OR 0.09 (0.0-0.6), were associated with RE.
In erysipelas located in the head or face (n = 50), only
14% were RE and none of the examined covariates were
associated with recurrence in univariable analyses, data
not shown.
Complete case analyses
Missingness for CRP, WBC and time since onset of
symptoms was highly dependent on hospitalization, but
evenly distributed among individuals with RE and SE.
The distributions of values from complete cases and im-
puted values in different strata of hospitalization were
very similar. Estimates from additional analyses using
Table 1 Clinical presentation in individuals with first and










Age, years (SD) 58.0 (18.7) 61.5 (16.1) 0.05
Gender,% male 211 (58.6) 75 (52.8) 0.24
Time since onset <0.01
<12 hrs 47 (13.1) 39 (27.5)
13-48 hrs 144 (40.0) 49 (34.5)
>48 hrs 85 (23.6) 29 (20.4)
Missing 84 (23.3) 25 (17.6)
Localization1) <0.01
Lower limbs 231 (64.2) 111 (78.2)
Upper limbs 60 (16.7) 15 (10.6)
Thorax/trunk 24 (6.7) 11 (7.6)
Head/face 45 (12.5) 6 (3.5)
CRP, median (range) 88 (0–513) 66 (2–438) 0.28
Missing 57 (15.8) 29 (20.4) 0.22
WBC, median (range) 11 (2.7-68) 13 (2.6-28) 0.82
Missing 73 (20.3) 31 (21.8) 0.70
Inpatient treatment 211 (58.6) 67 (47.2) 0.03
Initial iv antibiotics 239 (67.0) 84 (59.6) 0.18
Length of hospital
stay, median (range)
5 (1–34) 5 (1–22) 0.61
1)-Global p-value from likelihood ratio test <0.01).
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only complete cases yielded very little deviation from
analyses including imputed values and did not change
the conclusions drawn, see Additional file 1.
Discussion
In this large study of over 500 patients with erysipelas,
we found lymphedema to be the most prominent risk
factors for recurrence although the distribution of pre-
disposing conditions varies depending on the site of ery-
sipelas. In erysipelas in the head or face, none of the
investigated factors were associated with recurrence.
There are only a few studies regarding risk factors for
RE, although previous results are generally in line with
ours, most previous studies have neither been powered
enough to allow for multivariable adjustments for coex-
isting risk factors nor to assess effect modification by the
site of erysipelas [11,15,18-21]. Predisposing conditions
for recurrent erysipelas located in the head or face has
to the best of our knowledge not been studied previously.
Our results show that there is a strong heterogeneity in
the estimates from different sites of erysipelas, both in the
propensity for recurrence and among the individual risk
factors for recurrence, therefore analyses must be done
separately for each site.
It is well known that women treated for breast cancer
are at risk for ipsilateral erysipelas, especially if lymph-
edema develops [14,22]. Pavlotsky et al. found cardiac
disease, malignancy and lymphedema to be associated
with RE in the upper limbs in univariable analyses, but
effect sizes are not given [18]. We found local operation
and lymphedema to be strongly associated with RE, al-
though it is difficult to obtain reliable estimates due to
the complex relationship between tumor, surgery per-
formed, radiation therapy, lymphedema and infection as
outlined in Figure 1. In line with previous findings, we
did not find evidence for radiation therapy to be a risk
factor for recurrence [23].
Oddly, we found COPD to be protective against RE in
the lower limbs even when adjusting for multiple covar-
iates, this might be a spurious association or, more
Table 2 Distribution of underlying factors in individuals with single or recurrent episodes of erysipelas
Single episode Recurrent episodes Odds ratio (95% CI) p-value
n = 360 (100%) n = 142 (100%)
Age, years (95% CI) 58.0 (56.1-60.0) 61.5 (58.6-64.1) 1.1 (1.0-1.2) 0.05
Gender, % male 211 (58.6) 75 (52.8) 0.8 (0.5-1.2) 0.36
Local operation 71 (19.7) 46 (32.4) 2.0 (1.3-3.0) <0.01
CABG1) 16 (4.4) 13 (9.2) 2.2 (1.0-4.6) 0.05
Localization
Lower limbs 231 (64.2) 111 (78.2) 1 (reference) <0.01
Upper limbs 60 (16.7) 15 (10.6) 0.5 (0.3-0.9)
Thorax/trunc 24 (6.7) 11 (7.6) 0.9 (0.4-2.0)
Head/face 45 (12.5) 6 (3.5) 0.3 (0.1-0.7)
Skin disease 42 (11.7) 24 (16.9) 1.5 (0.9-2.6) 0.12
Malignancy 53 (14.7) 36 (25.4) 2.0 (1.2-3.7) <0.01
Radiation therapy 17 (4.7) 11 (7.8) 1.7 (0.8-3.7) 0.19
Immuno-suppressive therapy 36 (14.1) 8 (8.2) 0.5 (0.2-1.2) 0.14
Arterial insufficiency 13 (3.6) 8 (5.6) 1.6 (0.6-3.9) 0.32
Venous insufficiency1) 16 (4.4) 16 (11.3) 2.7 (1.3-5.6) <0.01
Lymphedema 8 (2.2) 19 (13.4) 6.8 (2.9-15.9) <0.01
Diabetes mellitus 52 (14.4) 25 (17.6) 1.3 (0.8-2.1) 0.38
Polyneuropathy 11 (3.1) 4 (2.8) 0.9 (0.3-2.9) 0.89
Vascular disease 62 (17.2) 24 (16.9) 1.0 (0.6-1.6) 0.93
COPD 22 (6.1) 3 (2.1) 0.3 (0.1-1.1) 0.09
Systemic inflammatory disease 16 (4.5) 4 (2.8) 0.6 (0.2-1.8) 0.41
Wound 176 (49.0) 53 (37.3) 0.6 (0.4-0.9) 0.02
Toe web intertrigo1) 10 (2.8) 8 (5.6) 2.1 (0.8-5.4). 0.13
Severe obesitas 1 (0.3) 4 (2.8) 10.4 (1.2-93.9) 0.04
Liver disease 9 (2.5) 4 (2.8) 1.1 (0.3-3.7) 0.84
1)-Calculated in the 342 individuals with erysipelas in the lower limbs, 229 and 113 respectively.
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speculatively, due to a high use of antibiotics directed
against airway pathogens in these patients which could
reduce the colonizing burden of causative agents, e. g.
group A streptococci.
It has been suggested that RE has a more severe dis-
ease presentation as measured by peak CRP and WBCs,
length of fever and length of hospital stay [15]. However,
these estimates were not adjusted for time since onset of
symptoms or site of infection. We did not find evidence
for differences in inflammatory parameters when taking
time since onset of symptoms and potential confounders
into account. Rerunning analyses, including only inpatient
treated individuals, yielded similar results. It is possible
that the lower propensity for hospitalization in patients
with RE could be attributed to a higher threshold among
doctors for hospitalization and treatment with intraven-
ous antibiotics, since patients with RE have experience
of the disease.
This study has several strengths. It is one of the largest
of its kind, which permits analyses of erysipelas per site
of infection as well as adjustments for coexisting risk
factors. We based our analyses on data collected from
the medical charts, thus there was no risk of biased recall
of information. Swedish health care is publicly financed
and all inpatient care is provided independently of health
insurance and the patient’s financial status. A unique, life-
long ten-digit personal identity number assigned to each
person living in Sweden provides the possibility of linking
records in health care databases which limits the risk of
biased selection. Erysipelas is by tradition cared for, at
Skåne University Hospital, by specialists of infectious dis-
ease. We included all patients who were diagnosed with
erysipelas at the Department of Infectious Diseases at
Skåne University Hospital, during the study period.
There are also some limitations to this study. The retro-
spective design allow only available information restricted
to medical records. Data were extracted according to a
pre-specified protocol but some covariates may still be
subject to interpersonal differences in the assessments.
The fraction of missing information on BMI was 81%,
why it was not considered reliable to impute values. In-
stead information on “severe obesity” was used, which was
considered highly specific but with low sensitivity. If BMI-
values for all participants had been available, the point
estimates for obesity (as defined by BMI-values), would
probably have been statistically significant but diluted.
Patients were admitted to the Department of Infectious
Diseases, although both as outpatient and inpatient, there
is likely to be a bias towards patients with more severe dis-





Figure 1 Directed acyclic graph (DAG) over relationship between
predisposing conditions in erysipelas of the upper limbs.
Table 3 Comparison between predisposing conditions of erysipelas in the lower limbs
Single episode Recurrent episode OR (95% CI) from
univariable analysis
p-value OR (95% CI) from
multivariable analysis1)
p-value
n = 231 (100%) n = 111 (100%) (95% CI) (95% CI)
CABG 11 (4.8) 11 (9.7) 2.2 (0.9-5.2) 0.08 2.0 (0.8-5.1) 0.12
Skin disease 26 (11.3) 23 (20.7) 2.1 (1.1-3.8) 0.02 1.9 (1.0-3.7) 0.05
Severe obesity 1 (0.4) 4 (3.6) 8.5 (0.9-77.9) 0.06 4.6 (0.5-45.8) 0.19
Venous insufficiency 14 (6.1) 16 (14.4) 2.6 (1.2-5.6) 0.02 2.3 (1.0-5.2) 0.05
Lymphedema 6 (2.6) 9 (8.1) 3.3 (1.1-9.5) 0.03 4.3 (1.3-14.0) 0.02
Local wound 118 (51.1) 49 (44.1) 0.8 (0.5-1.2) 0.23 0.8 (0.5-1.3) 0.42
COPD 15 (6.5) 2 (1.8) 0.3 (0.06-1.2) 0.08 0.2 (0.04-1.0) 0.05
Diabetes mellitus 44 (19.1) 20 (18.0) 0.9 (0.5-1.7) 0.82
Malignancy 20 (8.7) 14 (12.6) 1.5 (0.7-3.1) 0.29
Toe web intertrigo 10 (4.3) 8 (7.2) 1.7 (0.7-4.5) 0.27
Local operation2) 49 (21.2) 27 (24.3) 1.2 (0.7-2.0) 0.28
1)-Adjusted for all of the variables in the column; 2)-CABG included.
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infectious disease is differential for patients with SE and
RE, estimates could have been biased.
During the average two-year period of follow up, 3.3%
of the primarily naïve patients, experienced recurrence.
Some of the patients classified as SE will probably later
experience recurrence, this misclassification will bias es-
timates towards the null.
Conclusion
This study shows that a large proportion of cases with
erysipelas are RE but these episodes do not seem to be
more severe than SE. The most prominent risk factor for
recurrence is lymphedema, regardless of the site of erysip-
elas, and other conditions causing a chronic impairment
of the defence against microbes. Whereas conditions, tem-
porarily disrupting the skin barrier (e.g. a local wound or
toe web intertrigo), although being risk factors for ery-
sipelas per se, did not seem to predispose to repeated
episodes.
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